?
PROWESS
2001 Sepsis
? ICUs
1690 patients
Xigris for severe sepsis - 96hrs drotrecogin alpha. Benefit in subgroup APACHEII > 25
Clinical Question
In patients with septic shock, does Activated Protein C (also known as
drotrecogin alfa or DrotAA) compared with placebo reduce mortality?
Critical Appraisal
Key findings
Recombinant APC > RRR 19%, ARR 6% - NNT 16. Non-sig inc in serious bleeding NNH 67
- Population
- Sepsis
- Population Details
- Septic shock
- Intervention Arms
-
Activated Protein C
- Control Arms
-
Placebo
- Primary Outcome
- 28 day mortality
- Secondary Outcomes
- Not recorded
- P Value
- 0.31
Outcome Results
Not recorded